专利号:US-2025281509-A1 优先权日:2021-04-26 标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer 发明人:DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER 权利人:UNIV JOHNS HOPKINS 摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.
摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198 参考文献:10.1016/j.jsbmb.2007.09.024 摘要:Pinel G, Rambaud L, Cacciatore G, Bergwerff A, Elliott C, Nielen M, Le Bizec B. Elimination kinetic of 17β-estradiol 3-benzoate and 17β-nandrolone laureate ester metabolites in calves’ urine. The Journal of Steroid Biochemistry and Molecular Biology. 2008 May;110(1-2):30–8. doi: 10.1016/j.jsbmb.2007.09.024. 参考文献:10.1016/j.jsbmb.2010.01.012 摘要:Pinel G, Rambaud L, Monteau F, Elliot C, Le Bizec B. Estranediols profiling in calves’ urine after 17β-nandrolone laureate ester administration. The Journal of Steroid Biochemistry and Molecular Biology. 2010 Aug;121(3-5):626–32. doi: 10.1016/j.jsbmb.2010.01.012.